

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

WATSON LABORATORIES, INC.,
Petitioner,

v.

UNITED THERAPEUTICS CORP.

Patent Owner.

Case No. IPR2017-01622
Patent No. 9,339,507

**PETITIONER'S UPDATED EXHIBIT LIST
(AS OF JANUARY 25, 2018)**

Mail Stop PATENT BOARD
Patent Trial and Appeal Board
United States Patent and Trademark Office
PO Box 1450
Alexandria, Virginia 22313-1450
Submitted Electronically via the Patent Review Processing System

PETITIONER'S EXHIBIT LIST
(as of January 25, 2018)

Exhibit	Description
1001	U.S. Patent No. 9,339,507
1002	Declaration of Maureen D. Donovan in Support of the Petition for Inter Partes Review of U.S. Patent No. 9,339,507
1003	Robert Voswinckel, et al. "Inhaled treprostinil sodium for the treatment of pulmonary hypertension" Abstract #1414, <i>Circulation</i> , 110, 17, Supplement (Oct. 2004): III-295 ("Voswinckel")
1004	U.S. Patent Application Publication No. 2004/0265238 A1 to Chaudry ("Chaudry")
1005	Hossein Ardeschi Ghofrani, Robert Voswinckel, et al., "Neue Therapieoptionen in der Behandlung der pulmonalarteriellen Hypertonie," <i>Hertz</i> , 30,4 (June 2005): 296-302 ("Ghofrani")
1006	Opti-Neb-ir® Operating Instructions, Model ON-100/2 (2005)
1007	RESERVED
1008	Venta-Neb-ir® A-I-C-I Operating Instructions, Model VN-100/4
1009	Annexes to Commission Decision C(2005)3436 of 05 September 2005, http://ec.europa.eu/health/documents/community-register/2005/2005090510259/anx_10259_en.pdf (Annex III – Ventavis® Labelling and Package Leaflet)
1010	U.S. Patent No. 6,606,989 ("Brand '989")
1011	Amendment and Reply Accompanying RCE filed in 12/591,200 (Jul. 2, 2013) (with accompanying Declaration of Lewis Rubin, M.D.)
1012	WO 93/00951 to Patton
1013	Declaration of Scott Bennett, Ph.D.
1014	Affidavit of Christopher Butler, June 15, 2017
1015	Affidavit of Christopher Butler, June 16, 2017
1016	RESERVED
1017	RESERVED
1018	U.S. Patent No. 6,521,212 ("Cloutier '212")
1019	U.S. Patent No. 4,306,075 ("Aristoff '075")
1020	U.S. Patent No. 5,190,972 ("Dumble '972")
1021	European Patent Specification 0347243 B1, published January 13, 1993
1022	U.S. Patent No. 6,261,539 ("Adjei '539")
1023	European Patent Application Publication No. EP 0372777 A2 ("Purewal EP '777")

Exhibit	Description
1024	U.S. Patent No. 4,895,719 (“Radhakrishnan ’719”)
1025	U.S. Patent No. 5,153,222 (“Tadepalli ’222”)
1026	U.S. Patent No. 6,357,671 (“Cewers ’671”)
1027	Gessler, et al., <i>Ultrasonic versus Jet Nebulization of Iloprost in Severe Pulmonary Hypertension</i> , Eur. Respiratory J., 17:14-19 (2001)
1028	Olschewski H., et al., <i>Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension</i> , 1996 Ann. Intern. Med. 124(9), 820-824 (1996) (“Olschewski 199”)
1029	Olschewski, et al., <i>Pharmacodynamics and Pharmacokinetics of Inhaled Iloprost, Aerosolized by Three Different Devices, in Severe Pulmonary Hypertension</i> , Chest J., 124(4), 1294-1304 (Oct. 2003)
1030	Byron, <i>Drug Delivery Devices: Issues in Drug Development</i> , Proc. Am. Thorac. Soc., 1:321-328 (2004)
1031	U.S. Patent No. 5,544,646 (“Lloyd”)
1032	Edwards D.A. et al., <i>Recent Advances in Pulmonary Drug Delivery Using Large Porous Inhaled Particles</i> , Journal of Applied Physiology, 85(2): 379-385 (1998) (“Edwards 1998”)
1033	Badesch, et al., <i>Prostanoid Therapy for Pulmonary Arterial Hypertension</i> , J. of the Am. C. of Cardiology, 43(12):Suppl. S (2004)
1034	U.S. Patent No. 6,054,486 (“Crow ’486”)
1035	U.S. Food and Drug Administration, Drug Approval Package: Remodulin® (approved on May 21, 2002), http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-272_Remodulin.cfm (“Remodulin® Approval Package”)
1036	Electronic Medicines Compendium, Ventavis®, http://www.medicines.org.uk/emc/medicine/13743
1037	<i>European Agency Approves Ventavis for Primary Pulmonary Hypertension</i> , P&T Community (Sep. 22, 2003), https://www.ptcommunity.com/news/2003-09-22-000000/european-agency-approves-ventavis-primary-pulmonary-hypertension
1038	EU Community Register of Medicinal Products, Homepage, http://ec.europa.eu/health/documents/community-register/html/index_en.htm
1039	EMA Scientific Discussion, Ventavis® (2004), http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Scientific_Discussion/human/000474/WC500048688.pdf

Exhibit	Description
1040	Muller et al., "Use of Inhaled Iloprost in a Case of Pulmonary Hypertension during Pediatric Congenital Heart Surgery," 99 <i>Anesthesiology</i> 743-747 (2003)
1041	Mueller et al., "Inhaled Iloprost in the Management of Pulmonary Hypertension in Infants Undergoing Congenital Heart Surgery," 21 <i>Eur. J. Anaesthesiology</i> (suppl. 33) 2-36 (2004)
1042	Commission Decision C(2005)3436 of 05 September 2005, http://ec.europa.eu/health/documents/community-register/2005/2005090510259/dec_10259_en.pdf
1043	EU Community Register of Medicinal Products for Human Use, Ventavis, http://ec.europa.eu/health/documents/community-register/html/h255.htm#
1044	Summary of Community Decisions, Official Journal of the European Union (Oct. 28, 2005) http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.C_.2005.268.01.0002.01.ENG&toc=OJ:C:2005:268:TOC (noting a modification of marketing approval for Ventavis®)
1045	Electronic Medicines Compendium, Ventavis®, http://www.medicines.org.uk/emc/history/13743#version1 (noting a change to section 4.2 – Posology and Method of Administration on September 22, 2005)
1046	Voswinckel, R., et al., "Inhaled treprostinil is a potent pulmonary vasodilator in severe pulmonary hypertension," 25 <i>European Heart Journal</i> 22, at 218 (2004) ("Voswinckel II")
1047	Sulica, R and Poon, M. "Medical Therapeutics for Pulmonary Arterial Hypertension From Basic Science and Clinical Trial Design to Evidence-Based Medicine." 3(2) <i>Expert Rev. Cardiovas. Ther.</i> 347-360 (2005)
1048	<i>American Heart Association's Scientific Sessions 2004 – Largest Cardiovascular Meeting Plans to 'Jazz It Up' in New Orleans</i> , PR Newswire (Oct. 13 2004), http://www.prnewswire.com/news-releases/american-heart-associations-scientific-sessions-2004---largest-cardiovascular-meeting-plans-to-jazz-it-up-in-new-orleans-74293197.html#
1049	EU Community Register of Medicinal Products, Frequently Asked Questions, http://ec.europa.eu/health/documents/community-register/register_faq_2015.pdf

Exhibit	Description
1050	Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004, http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:136:0001:0033:en:PDF
1051	Register of Commission Documents, European Union, https://ec.europa.eu/transparency/regdoc/index.cfm?fuseaction=home
1052	Regulation (EC) No. 1049/2001 of the European Parliament and of the Council of 30 May 2001, http://www.europarl.europa.eu/RegData/PDF/r1049_en.pdf
1053	Register of the Commission Documents, European Commission, https://ec.europa.eu/transparency/regdoc/index.cfm?fuseaction=list&n=10&adv=0&coteId=&year=2005&number=3436&version=ALL&dateFrom=&dateTo=&serviceId=&documentType=&title=&titleLanguage=&titleSearch=EXACT&sortBy=NUMBER&sortOrder=DESC (search result for document search of Commission reference number '3436' for year '2005')
1054	U.S. Patent No. 5,234,953 ("Crow '953")
1055	Declaration of DeForest McDuff, Ph.D.
1056	U.S. Patent No. 9,358,240
1057	U.S. Patent No. 6,756,033
1058	Amendment and Reply filed in 13/469,854 (Jan. 4, 2013) (with accompanying Declaration of Lewis Rubin, M.D.)
1059	Reply in 13/469,854 (June 13, 2014)
1060	William F. Ganong, Review of Medical Physiology 591-92 (17th ed. 1995)
1061	Actelion Pharmaceuticals, "Actelion Announces Full Year 2003 Financial Results" (March 2, 2004)
1062	Actelion Pharmaceuticals, "Actelion Announces Full Year 2005 Financial Results" (Feb. 23, 2006)
1063	Actelion Pharmaceuticals, Annual Report, 2002
1064	Actelion Pharmaceuticals, Annual Report, 2006
1065	Actelion Pharmaceuticals, Annual Report, 2007
1066	Actelion Pharmaceuticals, Annual Report, 2008
1067	Actelion Pharmaceuticals, Annual Report, 2010
1068	Actelion Pharmaceuticals, Annual Report, 2011
1069	Actelion Pharmaceuticals, Annual Report, 2012
1070	Actelion Pharmaceuticals, Annual Report, 2013
1071	Actelion Pharmaceuticals, Annual Report, 2014

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.